Gimmy to List on Innovation Board in May, Optimizing Product Portfolio for Growth and Profit
Gimmy Biological Technology, a major gene sequencing company, is set to list on the Innovation Board in early May, with an initial offering price of NT$25 per share. General Manager Chiang Chun-chi stated that the company will optimize its product portfolio, increase the proportion of high-margin diagnostic products, and expand into the Asia-Pacific market. Gimmy aims for balanced growth and profitability, leveraging its DNA sequencing technology and multi-omics laboratories.
📋 Article Processing Timeline
- 📰 Published: April 14, 2026 at 21:59
- 🔍 Collected: April 14, 2026 at 22:31 (31 min after Published)
- 🤖 AI Analyzed: April 15, 2026 at 18:38 (20h 6m after Collected)
TAIPEI (CNA) – Gimmy Biological Technology, a major gene sequencing company, is expected to list on the Innovation Board in early May, with a tentative offering price of NT$25 per share. Gimmy General Manager Chiang Chun-chi stated that this year, the company will optimize its product portfolio, increase the proportion of high-margin diagnostic products, and expand into the Asia-Pacific market, while also introducing automation to enhance efficiency, driving operations towards balanced growth and profitability.
Gimmy, Taiwan's commercial genomics sequencing company, was established in 2001 and held a media briefing today. Gimmy Chairman Chou Meng-hsien stated that Gimmy's core technology originates from the DNA sequencing field, possessing genomics and multi-omics (integrating multiple biological data analyses) laboratories, providing sequencing technology platforms and the ability to process large numbers of samples simultaneously.
He noted that during the pandemic, in addition to supporting domestic gene testing needs, the company also transformed to establish nucleic acid and peptide synthesis facilities compliant with regulations. Currently, it has developed a kiloton-scale production process for nucleic acid vaccine adjuvants and provides short-chain nucleic acid drug APIs, while also developing CRDMO (Contract Research, Development, and Manufacturing Organization) services. Furthermore, Gimmy is simultaneously expanding clinical testing and agency services.
He pointed out that benefiting from NGS (Next-Generation Sequencing) and multi-omics projects, coupled with a doubling of instrument agency business, Gimmy's revenue in 2025 reached NT$708 million, a year-on-year increase of 36.86%, setting a new historical high. In the first quarter of this year, with steady development in its four major businesses—multi-omics research services, clinical testing, CRDMO, and instrument agency—revenue was NT$151 million, a year-on-year increase of 24.66%, maintaining a growth trend.
Looking ahead to this year, Chiang Chun-chi stated that through three major directions—product portfolio optimization, regional market expansion, and technology upgrading—the company will shift from pursuing revenue growth to focusing on both growth and profitability, aiming for sustainable development and maintaining long-term competitiveness.
Chiang Chun-chi said that this year, the company will continue to increase the revenue proportion of high-margin proprietary diagnostic products, such as precision medical testing, to optimize operations. Secondly, by enhancing sequencing capacity and introducing automated processes, it will reduce unit costs and improve economies of scale and operational efficiency.
In addition, Gimmy will collaborate with partners to expand into the Asia-Pacific market and enlarge its testing service scale. Chiang Chun-chi is optimistic about this year. (Edited by Chang Liang-chih) 1150414
Gimmy, Taiwan's commercial genomics sequencing company, was established in 2001 and held a media briefing today. Gimmy Chairman Chou Meng-hsien stated that Gimmy's core technology originates from the DNA sequencing field, possessing genomics and multi-omics (integrating multiple biological data analyses) laboratories, providing sequencing technology platforms and the ability to process large numbers of samples simultaneously.
He noted that during the pandemic, in addition to supporting domestic gene testing needs, the company also transformed to establish nucleic acid and peptide synthesis facilities compliant with regulations. Currently, it has developed a kiloton-scale production process for nucleic acid vaccine adjuvants and provides short-chain nucleic acid drug APIs, while also developing CRDMO (Contract Research, Development, and Manufacturing Organization) services. Furthermore, Gimmy is simultaneously expanding clinical testing and agency services.
He pointed out that benefiting from NGS (Next-Generation Sequencing) and multi-omics projects, coupled with a doubling of instrument agency business, Gimmy's revenue in 2025 reached NT$708 million, a year-on-year increase of 36.86%, setting a new historical high. In the first quarter of this year, with steady development in its four major businesses—multi-omics research services, clinical testing, CRDMO, and instrument agency—revenue was NT$151 million, a year-on-year increase of 24.66%, maintaining a growth trend.
Looking ahead to this year, Chiang Chun-chi stated that through three major directions—product portfolio optimization, regional market expansion, and technology upgrading—the company will shift from pursuing revenue growth to focusing on both growth and profitability, aiming for sustainable development and maintaining long-term competitiveness.
Chiang Chun-chi said that this year, the company will continue to increase the revenue proportion of high-margin proprietary diagnostic products, such as precision medical testing, to optimize operations. Secondly, by enhancing sequencing capacity and introducing automated processes, it will reduce unit costs and improve economies of scale and operational efficiency.
In addition, Gimmy will collaborate with partners to expand into the Asia-Pacific market and enlarge its testing service scale. Chiang Chun-chi is optimistic about this year. (Edited by Chang Liang-chih) 1150414